Profiel
Harish Shantharam is currently the Chief Financial Officer at UCLA Anderson School of Management.
Previously, he served as the Chief Financial & Accounting Officer at CymaBay Therapeutics, Inc. from 2023 to 2024.
Prior to that, he was the Vice President-Global Commercial Finance at Gilead Sciences, Inc. from 2011 to 2022.
He also held the position of Head-Business Development at Amgen, Inc. from 2004 to 2011.
Mr. Shantharam holds a graduate degree from The University of Texas at Arlington and an MBA from UCLA Anderson School of Management.
Eerdere bekende functies van Harish Shantharam
| Bedrijven | Functie | Einde |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Director of Finance/CFO | 22-03-2024 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01-05-2022 |
| AMGEN INC. | Corporate Officer/Principal | 01-11-2011 |
Opleiding van Harish Shantharam
| The University of Texas at Arlington | Graduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
